Forest, Ironwood’s Just-Approved Chronic Constipation Drug Has Blockbuster Potential, Analyst Says

Drug Industry Daily
A A
The FDA has approved Forest Laboratories and Ironwood Pharmaceuticals’ Linzess to treat chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. 

To View This Article:

Login

Subscribe To Drug Industry Daily